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Objective: Fine-needle aspiration cytology (FNAC) is considered to be the most reliable
method of examination for thyroid nodules. However, when thyroid nodules are evaluated
as Bethesda I–V, the role of ultrasonography is considered to be enhanced. We investi-
gated the association between a number of ultrasonographic (US) characteristics and the
risk of thyroid malignancy, and assessed the optimal compromise on the number of US
characteristics for predicting thyroid malignancy.
Methods: Seventy-three patients, whose thyroid nodules were evaluated as Bethesda I–V
by FNAC prior to surgery, were treated surgically. A number of US characteristics, such
as microcalcification, irregular margins, hypoechogenicity, a taller-than-wide shape, and
the absence of halo sign, were assessed before surgery. The optimal compromise on the
number of US characteristics was analyzed using a receiver operating characteristics (ROC)
curve. The area under the ROC curve (AUC) represents the overall discriminatory ability of
a test.
Results: The risk of malignancy was 11.8% in patients without any US characteristics,
44.4% in those with one characteristic, 61.5% in those with two characteristics, 75% in
those with three characteristics, 90% in those with four characteristics, and 100% in those
with five characteristics. The AUC was favorable (0.81599). At least two US characteristics
were revealed to be the optimal compromise on the number of US characteristics based
on the ROC curve.
Conclusion: We proved the role of the number of US characteristics in predicting thyroid
malignancy. It was thought that a surgical approach should be considered for patients with
at least two US characteristics.
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INTRODUCTION
Fine-needle aspiration cytology (FNAC) is considered as the most
reliable method of examination by which to make decisions
regarding surgical treatment for patients with thyroid nodules (1,
2). To standardize FNAC reports, the National Cancer Institute
(NCI) hosted an “NCI thyroid fine-needle aspiration state of the
science conference,” which led to the formation of “The Bethesda
system for reporting thyroid cytopathology” (3–5). On the other
hand, ultrasonography has been reported to be effective in pre-
dicting thyroid malignancies (6, 7). We believe that the role of
ultrasonography is enhanced for patients with nodules that were
not diagnosed definitively as malignant by FNAC. We assessed the
accuracy of each ultrasonographic (US) characteristic for patients
with thyroid nodules classified as Bethesda I–V. We also focused
on the number of US characteristics, and determined the optimal
compromise on the number of US characteristics for predicting
thyroid malignancies.
MATERIALS AND METHODS
PATIENTS
A total of 185 patients with thyroid nodule were surgically treated
between July 2010 and December 2013 in the Department of
Otolaryngology-Head and Neck Surgery, Hokkaido University,
Sapporo, Japan. Of these, 73 patients, whose thyroid nodules were
evaluated as Bethesda I–V by FNAC before surgery, were eligible
for this study. These patients consisted of 52 women and 21 men,
with a median age of 58 years old (range, 24–77 years). Approval
for this study was obtained from the institutional review board of
Hokkaido University.
PREOPERATIVE EVALUATION AND ULTRASONOGRAPHIC DIAGNOSTIC
CRITERIA
Certified head and neck surgeons performed ultrasonography for
patients with thyroid nodules before surgery using a HI VISION
Ascendus system (HITACHI ALOKA Medical, Tokyo, Japan).
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Table 1 |The modified ultrasonographic diagnostic criteria.
Microcalcification Nodules defined as positive if any one of these
characteristics were observedIrregular margins
Hypoechogenicity
Taller-than-wide shape
Absence of halo sign
Thyroid nodules were evaluated by B mode, and nodule size was
recorded. US characteristics, such as microcalcification, irregu-
lar margins, hypoechogenicity, taller-than-wide shape, and the
absence of halo sign, were assessed according to previous reports
(6, 7). The US diagnostic criteria defined nodules as positive if any
one of these five characteristics were observed (Table 1). FNAC
was performed before surgery for all patients with a 21-gage nee-
dle attached to a 50 cc disposable syringe using US guidance. Two
alcohol-fixed smears were prepared for Papanicolaou staining. On-
site evaluation was not performed routinely. FNAC was evaluated
by pathologists in accordance with the Bethesda system (3–5).
SURGICAL TREATMENT AND POSTOPERATIVE EVALUATION
Lobectomy or total thyroidectomy was performed based on the
result of FNAC, the extent of nodules, the nodal status, or the
patient’s wishes. Paratracheal nodal dissection or lateral neck dis-
section was added according to the nodal status. The removed
thyroid nodules were assessed pathologically.
STATISTICAL ANALYSIS
We calculated sensitivity, specificity, positive predictive value
(PPV), and negative predictive value (NPV) for each US char-
acteristic. The risk of malignancy was also calculated according to
the number of US characteristics. The optimal compromise on the
number of US characteristics was analyzed using a receiver oper-
ating characteristics (ROC) curve. The ROC curve plots sensitivity
against (one-specificity) for all possible thresholds in a binary clas-
sification task. The area under the ROC curve (AUC) represents
the overall discriminatory ability of a test, where a value of 1.0
denotes perfect ability and a value of 0.5 denotes no ability.
RESULTS
THE BETHESDA CLASSIFICATION
Thyroid nodules were evaluated as non-diagnostic or unsatis-
factory (Bethesda I) in 10 patients, benign (Bethesda II) in 22
patients, atypia of undetermined significance or follicular lesion
of undetermined significance (Bethesda III) in 12 patients, follic-
ular neoplasm, or suspicious for a follicular neoplasm (Bethesda
IV) in 9 patients, and suspicious for malignancy (Bethesda V) in
20 patients by FNAC.
SURGERY AND FINAL PATHOLOGICAL RESULTS
The reason for surgery was suspicious for malignancy by FNAC in
20 patients, the presence of US abnormalities in 35 patients, large
size (>3 cm) in 12 patients, and the patient’s wish for a diagnostic
lobectomy instead of repeat FNAC in 6 patients.
Based on final pathological results, benign lesions were
observed in 34 patients, consisting of 24 cases of adenomatous
goiter, 9 of follicular adenoma, and 1 of benign cyst. Malignant
Table 2 |The risk of malignancy according to Bethesda classification.
Bethesda
classification
No. of
patients
Final pathology The risk of
malignancy (%)
Malignant Benign
I 10 6 4 60.0
II 22 8 14 36.4
III 12 5 7 41.7
IV 9 2 7 22.2
V 20 18 2 90.0
Table 3 |The correlation between final pathology and evaluation of the
ultrasonographic (US) criteria (sensitivity 94.9%, specificity 44.1%,
positive predictive value 66.1%, negative predictive value 88.2%).
Final pathology Total
Malignant Benign
US Criteria
Positive 37 19 56
Negative 2 15 17
Total 39 34 73
tumors were observed in 39 patients, consisting of one case of
anaplastic carcinoma, one of poorly differentiated carcinoma, 34
of differentiated papillary carcinoma, and 3 of minimally inva-
sive follicular carcinoma. Table 2 shows the correlation between
Bethesda classification and final pathological diagnosis.
US CHARACTERISTICS AND DIAGNOSTIC VALUE
The median maximum nodule diameter was 22 mm (range, 5–
70 mm). Microcalcification was observed in 30 patients, irregular
margins in 23 patients, hypoechogenicity in 24 patients, taller-
than-wide shape in 14 patients, and an absence of halo sign in 44
patients.
With the use of the modified US diagnostic criteria, 56 patients
were classified as positive. In 37 of these 56 patients, malignant
thyroid diseases were observed. When using diagnostic criteria,
the sensitivity, specificity, PPV, and NPV were calculated as 94.9,
44.1, 66.1, and 88.2%, respectively (Table 3).
Table 4 shows the sensitivity, specificity, PPV, and NPV for each
US characteristic and tumor size.
THE NUMBER OF US CHARACTERISTICS AND ROC CURVE ANALYSIS
Table 5 shows the risk of malignancy according to the number
of US characteristics. Sensitivity and specificity were indicated for
each number of US characteristics in Table 6. The analysis of the
association between the risk of malignancy and the number of
US characteristics is shown in Figure 1 with an ROC curve show-
ing the plots of all thresholds. The value of AUC was 0.81599.
At least two US characteristics was revealed to be the optimal
compromise on the number of US characteristics based on the
ROC curve.
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Table 4 | Diagnostic value of each ultrasonographic characteristic.
Characteristics Sensitivity Specificity PPV NPV
(%) (%) (%) (%)
Tumor size >3 cm 23.1 61.8 40.9 41.2
Microcalcification 59.0 79.4 76.7 62.8
Irregular margins 51.3 91.2 87.0 62.0
Hypoechogenicity 46.2 82.4 75.0 57.1
Taller-than-wide shape 30.8 94.1 85.7 54.2
Absence of halo sign 74.4 55.9 65.9 65.5
PPV, positive predictive value, NPV, negative predictive value.
Table 5 |The risk of malignancy according to the number of
ultrasonographic (US) characteristics.
The number of
US characteristics
No. of
patients
Final pathology The risk of
malignancy (%)
Malignant Benign
5 3 3 0 100.0
4 10 9 1 90.0
3 12 9 3 75.0
2 13 8 5 61.5
1 18 8 10 44.4
0 17 2 15 11.8
Table 6 |The sensitivity and specificity of each number of
ultrasonographic (US) characteristics for predicting thyroid
malignancies.
The number of US
characteristics
Sensitivity (%) Specificity (%)
5 7.7 100.0
4 30.8 97.1
3 53.9 88.2
2 74.4 73.5
1 94.9 44.1
0 100.0 0.0
ANALYSIS OF 34 CASES DIAGNOSED WITH DIFFERENTIATED
PAPILLARY CARCINOMA
Of 34 cases diagnosed with differentiated papillary carcinomas,
five cases were evaluated as Bethesda I, seven cases were evalu-
ated as Bethesda II, three cases were evaluated as Bethesda III, two
cases were evaluated as Bethesda IV, and 17 cases were evaluated
as Bethesda V. Of these 34, 3 patients had 5 US characteristics,
7 patients had 4 US characteristics, 9 patients had 3 US charac-
teristics, 8 patients had 2 US characteristics, 6 patients had 1 US
characteristic, and 1 patient had no US characteristics.
DISCUSSION
Both accuracy and value of FNAC for the preoperative evaluation
of thyroid nodules have been established. When the cytological
diagnosis is malignant, the PPV is >99%, and when it is benign,
the false negative is typically<5% (4, 8). On the other hand, many
FIGURE 1 |The receiver operating characteristics (ROC) curve showing
the predictive value for thyroid malignancy based on the number of
ultrasonographic (US) characteristics. The area under the ROC curve
(AUC) was 0.81599.
authors have also found ultrasonography to be effective in predict-
ing thyroid malignancies. Kim et al. reported the effectiveness of
the US diagnostic criteria, which was defined as positive if any one
of the US characteristics, such as microcalcification, irregular mar-
gins, hypoechogenicity, or taller-than-wide shape, was observed
(6). They applied these criteria to patients with thyroid nodules
and found that the sensitivity, specificity, PPV, and NPV were 94,
66, 56, and 96%, respectively. Rago et al. also reported that of the
absence of halo sign was useful in predicting thyroid malignan-
cies (7). In current study, we added this feature to the US criteria
reported by Kim et al., and evaluated these modified US diagnostic
criteria on patients with Bethesda I–V. We found that these crite-
ria had almost the same level of accuracy as that reported by Kim
et al. Although we did not find any evidence that a specific feature
was particularly effective in predicting thyroid malignancies, both
irregular margins and taller-than-wide shape had high PPVs (87
and 85.7%, respectively), and might be the most predictive char-
acteristics. In addition, we were unable to prove the efficacy of
nodule size in predicting thyroid malignancies. From the results
of our study, we believe that nodule size should not be included
in the US diagnostic criteria. The NPV of our criteria (88.2%)
was satisfactory. Therefore, it might be acceptable to recommend
repeat FNAC for patients without any US characteristics.
Smith-Bindman et al. suggested classifying patients with thy-
roid nodules according to the number of US characteristics, such
as nodule size (>2 cm), microcalcification, or solid nodules (9).
It was suggested that patients with <2 US characteristics have a
risk of malignancy of 5 per 1000 patients, so that it was consid-
ered acceptable for biopsy or diagnostic lobectomy to be deferred
in such patients. From the current study, our ROC curve analy-
sis indicated that at least two US characteristics were optimal
compromise, and we proved that the number of US characteristics
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was correlated significantly with the risk of malignancy, as the
AUC of the ROC curve showed a favorable value (0.81599). This
indicated that patients with at least two US characteristics had a
risk of malignancy of 76%. Although repeat FNAC is convenient
and minimally invasive, we believe that a surgical approach should
be considered for patients with at least two US characteristics.
Marchevsky et al. reviewed the risk of malignancies predicted by
FNAC. The rates of malignancies detected on thyroidectomy were
75% in patients with Bethesda I, 32.2% in those with Bethesda II,
37.9% in those with Bethesda III, 27.3% in those with Bethesda
IV, and 100% in those with Bethesda V (10). Although our results
were comparable to previous reports, it is regarded inevitable that
the risk of malignancy by FNAC classification should vary quite
markedly among institutions.
Ohori et al. reviewed the risk of malignancy in patients with
Bethesda III, and found that the risk ratio ranged from 6 to 48%
(11). Gweon et al. also reported the risk of malignancy based on
thyroidectomy and/or FNAC was 70% in patients with Bethesda
III. They found that the adoption of US evaluation elevated the
accuracy of the diagnosis of malignancies to 85–100% (12). From
these reports, it appears to be acceptable to make the decision
to perform surgery on the basis of US findings for patients with
thyroid nodules categorized as Bethesda III.
The limitations of this study include its retrospective nature,
and the limited study population. Our study was designed to deter-
mine how to reduce unnecessary and excessive thyroid surveillance
and lobectomy. Therefore, we limited inclusion eligibility to those
patients undergoing surgery and with Bethesda I–V nodules. Our
data might not, therefore, be applicable to every case with Bethesda
I–V nodules. In addition, the accuracy of the FNAC was very low in
our study. In previous reports, patients with thyroid nodules eval-
uated as Bethesda I–III were recommended for repeat FNAC or
clinical follow-up (4, 5). However, 44 patients with nodules eval-
uated as Bethesda I–III underwent thyroidectomy in our study.
If we undertook repeat FNAC for these 44 patients, the accuracy
of the FNAC would be improved. However, we would like to rec-
ommend that the decision to undertake thyroidectomy be based
on the number of US characteristics instead of repeat FNAC for
patients with thyroid nodules evaluated as Bethesda I–III.
We focused on 34 cases pathologically diagnosed with differ-
entiated papillary carcinoma. Of these 34, 12 were false negative
based on FNAC findings, including 7 with Bethesda II-benign,
3 with Bethesda III-atypia of undetermined significance or fol-
licular lesion of undetermined significance, and 2 with Bethesda
IV-follicular neoplasm. After excluding five cases with Bethesda
I-unsatisfactory, the false negative rate for FNAC was calculated as
41.4% (12/29). Using the criteria of at least two US characteristics,
false negative findings based on the number of US characteristics
were observed in seven patients (20.6%, 7/34). This focus on dif-
ferentiated papillary carcinomas reconfirmed the beneficial role
of the number of US characteristics due to the acceptable false
negative rate.
In conclusion, we applied a modified set of US criteria,
and proved the efficacy of the number of US characteristics
in predicting thyroid malignancies. We believe that a surgical
approach should be considered for patients with at least two US
characteristics.
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